Nirsevimab (Beyfortus) 100 mg Open for Ordering

To: Maine Immunization Program Providers  

From: Maine Immunization Program  

Subject: Nirsevimab (Beyfortus) 100 mg Open for Ordering 

Date: January 9, 2024

The Maine Immunization Program is pleased to announce that Nirsevimab (Beyfortus) 100 mg for infants is now open for ordering through ImmPact to enrolled Vaccines for Children (VFC) providers. Ordering is available at a minimum quantity of 5 doses and a maximum quantity of 10 doses per site. We ask that you only order what you will need during the remainder of the RSV season (end of March). Nirsevimab 50 mg doses will continue to be prioritized to birthing hospitals throughout Maine. 

On October 23, 2023, the Centers for Disease Control and Prevention (CDC) issued Health Alert Network (HAN) Health Advisory 499 to provide guidance for prioritization of nirsevimab given limited supply. Given the recent increase in nirsevimab supply, the CDC advises healthcare providers to return to recommendations put forward by CDC and the Advisory Committee on Immunization Practices (ACIP) on use of nirsevimab in young children. Infants and children recommended to receive nirsevimab should be immunized as quickly as possible. Healthcare providers should not reserve nirsevimab doses for infants born later in the season when RSV circulation and risk for exposure to RSV may be lower. RSV activity remains elevated nationwide and is continuing to increase in many parts of the country. 

Recommendations for Healthcare Providers

• In the setting of increasing supply, healthcare providers should administer a single dose of Nirsevimab to all infants aged less than 8 months, as well as children aged 8 through 19 months at increased risk.  
  • Healthcare providers should continue to work with their state immunization program and the manufacturer to order available nirsevimab doses. CDC is working closely with jurisdictional partners to ensure adequate supply through the Vaccines for Children Program.  
  • Neither RSV vaccine (Pfizer Abrysvo, GSK Arexvy) is approved for use in infants or young children. Healthcare providers should take care to use the correct product for the correct population. 
  • Although supply of nirsevimab is expected to increase, available supply may continue to vary locally and by healthcare facility. For healthcare providers who continue to have limited supply, nirsevimab should be prioritized to protect infants at the highest risk for severe RSV disease using the following principles: first by high-risk conditions and then by age, prioritizing the youngest infants first.